Aurinia Pharmaceuticals to Acquire Kezar Life Sciences in a $50.93 Million Deal
Aurinia Pharmaceuticals Inc. (AUPH) entered a merger agreement on March 30, 2026, to acquire Kezar Life Sciences, Inc. (KZR) in a deal valued at $50.93 million. Deal Structure:…
Written byAsif SuriaSource: InsideArbitrage
Aurinia Pharmaceuticals Inc. (AUPH) entered a merger agreement on March 30, 2026, to acquire Kezar Life Sciences, Inc. (KZR) in a deal valued at $50.93 million. Deal Structure: Aurinia will acquire Kezar Life Sciences for $6.955 per share in cash, plus one non-transferable contingent value right (CVR). The cash consideration represents a premium of 12.18%